Skip to main content
Fig. 5 | Cancer Nanotechnology

Fig. 5

From: Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)

Fig. 5

The cytotoxicity of αCD20/PLD against CD20+ lymphoma cells. a PLD (), αCD20/PLD () or αDNS/PLD () were incubated with CD20+ lymphoma cells for 12 h. The cell viability was determined by ATPlite analysis and the mean luminescence values were compared to untreated control cells (n = 3). Bars, SD. b The half-maximal inhibitory concentration (IC50) values of PLD, αCD20/PLD or αDNS/PLD. Bars, SD. *P < 0.05. **P < 0.01.; n.s. not significant

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us